A detailed history of State Street Corp transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, State Street Corp holds 2,945,060 shares of AUPH stock, worth $26.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,945,060
Previous 2,880,111 2.26%
Holding current value
$26.4 Million
Previous $16.4 Million 31.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.32 - $7.33 $345,528 - $476,076
64,949 Added 2.26%
2,945,060 $21.6 Million
Q2 2024

Aug 14, 2024

BUY
$4.81 - $5.78 $525,478 - $631,447
109,247 Added 3.94%
2,880,111 $16.4 Million
Q1 2024

May 15, 2024

BUY
$4.93 - $9.31 $327,756 - $618,947
66,482 Added 2.46%
2,770,864 $13.9 Million
Q4 2023

Feb 14, 2024

BUY
$7.13 - $9.49 $747,559 - $994,998
104,847 Added 4.03%
2,704,382 $24.3 Million
Q3 2023

Nov 14, 2023

SELL
$7.77 - $12.27 $256,029 - $404,308
-32,951 Reduced 1.25%
2,599,535 $20.2 Million
Q2 2023

Aug 14, 2023

BUY
$8.96 - $11.69 $470,167 - $613,421
52,474 Added 2.03%
2,632,486 $25.5 Million
Q1 2023

May 15, 2023

BUY
$5.94 - $11.27 $774,962 - $1.47 Million
130,465 Added 5.33%
2,580,012 $28.3 Million
Q4 2022

Feb 14, 2023

BUY
$4.11 - $8.14 $33,344 - $66,039
8,113 Added 0.33%
2,449,547 $10.6 Million
Q3 2022

Nov 15, 2022

BUY
$6.66 - $12.39 $356,789 - $663,757
53,572 Added 2.24%
2,441,434 $18.4 Million
Q2 2022

Aug 15, 2022

BUY
$8.95 - $12.8 $16.7 Million - $23.9 Million
1,863,594 Added 355.47%
2,387,862 $24 Million
Q1 2022

May 16, 2022

BUY
$10.05 - $22.48 $1.45 Million - $3.25 Million
144,586 Added 38.08%
524,268 $6.49 Million
Q4 2021

Feb 14, 2022

BUY
$17.78 - $33.08 $87,904 - $163,547
4,944 Added 1.32%
379,682 $8.68 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $4.1 Million - $8.83 Million
374,738 New
374,738 $8.29 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.27B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.